Top

European Archives of Oto-Rhino-Laryngology

Published in:

01-07-2021 | Radiotherapy | Head and Neck

Radiation-induced toxicities and outcomes after radiotherapy are independent of patient age in elderly salivary gland cancer patients: results from a matched-pair analysis of a rare disease

Authors: Alexander Rühle, Sofie Rothhaar, Erik Haehl, Tobias Kalckreuth, Tanja Sprave, Raluca Stoian, Constantinos Zamboglou, Eleni Gkika, Andreas Knopf, Anca-Ligia Grosu, Nils H. Nicolay

Published in: European Archives of Oto-Rhino-Laryngology | Issue 7/2021

Abstract

Purpose

This study analyzed survival and toxicity after (chemo)radiotherapy for primary salivary gland cancer patients aged ≥ 65 years and compared these results with younger patients using a matched-pair analysis.

Methods

Twenty-nine elderly patients with primary salivary gland carcinomas treated with (chemo)radiotherapy from 2008 to 2020 at University of Freiburg Medical Center were analyzed for oncological outcomes and therapy-associated toxicities. Local/locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan–Meier method, and the influence of clinical parameters on patient outcomes was assessed. A matched-pair analysis was performed after matching with patients < 65 years.

Results

Nine patients (31.0%) received definitive (chemo)radiotherapy, and 20 patients (69.0%) were treated in the adjuvant setting. 2-year LRC, PFS and OS ranged at 82.4%, 53.7% and 71.8%, respectively. Smoking (HR 3.980, p = 0.020), reduced performance status (HR 3.735, p = 0.016) and higher comorbidity burden (HR 4.601, p = 0.005) correlated with inferior OS. Using a matched-pair analysis with younger patients, elderly patients exhibited a trend towards reduced OS (HR 3.015, p = 0.065), but not PFS (HR 1.474, p = 0.371) or LRC (HR 1.324, p = 0.633). Acute and chronic grade 3 toxicities occurred in 31.0% and 12.5% of elderly patients, respectively, and the matched-pair analysis revealed no significant differences between age groups regarding treatment-related toxicities.

Conclusion

Treatment-related toxicities as well as LRC and PFS were comparable for salivary gland cancer patients undergoing radiotherapy. Therefore, concerns for more pronounced toxicities or reduced local/locoregional response rates should not guide treatment decisions in affected elderly patients.

Available only for authorised users

Bjørndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, Homøe P, Sørensen CH, Andersen E, Bundgaard T, Primdahl H, Lambertsen K, Andersen LJ, Godballe C (2011) Salivary gland carcinoma in Denmark 1990–2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 47(7):677–682. https://doi.org/10.1016/j.oraloncology.2011.04.020CrossRefPubMed

Pinkston JA, Cole P (1999) Incidence rates of salivary gland tumors: results from a population-based study. Otolaryngol Head Neck Surg 120(6):834–840. https://doi.org/10.1016/s0194-5998(99)70323-2CrossRefPubMed

Zarbo RJ (2002) Salivary gland neoplasia: a review for the practicing pathologist. Mod Pathol 15(3):298–323. https://doi.org/10.1038/modpathol.3880525CrossRefPubMed

Spiro RH (1986) Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8(3):177–184. https://doi.org/10.1002/hed.2890080309CrossRefPubMed

Wahlberg P, Anderson H, Biörklund A, Möller T, Perfekt R (2002) Carcinoma of the parotid and submandibular glands—a study of survival in 2465 patients. Oral Oncol 38(7):706–713. https://doi.org/10.1016/s1368-8375(02)00007-6CrossRefPubMed

Eneroth CM (1971) Salivary gland tumors in the parotid gland, submandibular gland, and the palate region. Cancer 27(6):1415–1418. https://doi.org/10.1002/1097-0142(197106)27:6<1415:aid-cncr2820270622>3.0.co;2-xCrossRefPubMed

Boukheris H, Curtis RE, Land CE, Dores GM (2009) Incidence of carcinoma of the major salivary glands according to the who classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomark Prev 18(11):2899–2906. https://doi.org/10.1158/1055-9965.Epi-09-0638CrossRef

Luukkaa H, Klemi P, Leivo I, Koivunen P, Laranne J, Mäkitie A, Virtaniemi J, Hinkka S, Grénman R (2005) Salivary gland cancer in Finland 1991–96: an evaluation of 237 cases. Acta Otolaryngol 125(2):207–214. https://doi.org/10.1080/00016480510003174CrossRefPubMed

Terhaard CH, Lubsen H, Van der Tweel I, Hilgers FJ, Eijkenboom WM, Marres HA, Tjho-Heslinga RE, de Jong JM, Roodenburg JL (2004) Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 26(8):681–692. https://doi.org/10.1002/hed.10400(discussion 692–683)CrossRefPubMed

10.

Eskander A, Irish J, Freeman J, Gullane P, Gilbert R, Groome PA, Hall SF, Urbach DR, Goldstein DP (2014) Overview of major salivary gland cancer surgery in Ontario (2003–2010). J Otolaryngol Head Neck Surg 43(1):50–50. https://doi.org/10.1186/s40463-014-0050-6CrossRefPubMedPubMedCentral

11.

Wedding U, Roehrig B, Klippstein A, Steiner P, Schaeffer T, Pientka L, Höffken K (2007) Comorbidity in patients with cancer: prevalence and severity measured by cumulative illness rating scale. Crit Rev Oncol Hematol 61(3):269–276. https://doi.org/10.1016/j.critrevonc.2006.11.001CrossRefPubMed

12.

Pignon JP, Le Maitre A, Maillard E, Bourhis J, Group M-NC (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14. https://doi.org/10.1016/j.radonc.2009.04.014CrossRefPubMed

13.

Haehl E, Ruhle A, David H, Kalckreuth T, Sprave T, Stoian R, Becker C, Knopf A, Grosu AL, Nicolay NH (2020) Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? Radiat Oncol 15(1):31. https://doi.org/10.1186/s13014-020-1481-zCrossRefPubMedPubMedCentral

14.

Rühle A, Haehl E, David H, Kalckreuth T, Sprave T, Stoian R, Zamboglou C, Gkika E, Knopf A, Grosu A-L (2020) The value of laboratory parameters for anemia, renal function, systemic inflammation and nutritional status as predictors for outcome in elderly patients with head-and-neck cancers. Cancers 12(6):1698CrossRefPubMedCentral

15.

Wang X, Luo Y, Li M, Yan H, Sun M, Fan T (2017) Management of salivary gland carcinomas—a review. Oncotarget 8(3):3946–3956. https://doi.org/10.18632/oncotarget.13952CrossRefPubMed

16.

Terhaard CH, Lubsen H, Rasch CR, Levendag PC, Kaanders HH, Tjho-Heslinga RE, van Den Ende PL, Burlage F (2005) The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 61(1):103–111. https://doi.org/10.1016/j.ijrobp.2004.03.018CrossRefPubMed

17.

Vartanian JG, Gonçalves Filho J, Kowalski LP, Shah JP, Suárez C, Rinaldo A, De Bree R, Rodrigo JP, Hamoir M, Takes RP, Mäkitie AA, Zbären P, Andreasen S, Poorten VV, Sanabria A, Hellquist H, Robbins KT, Bödeker CC, Silver C, Ferlito A (2019) An evidence-based analysis of the management of N0 neck in patients with cancer of the parotid gland. Expert Rev Anticancer Ther 19(10):899–908. https://doi.org/10.1080/14737140.2019.1674143CrossRefPubMed

18.

Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefebvre JL (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27(10):843–850. https://doi.org/10.1002/hed.20279CrossRefPubMed

19.

Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre J-L, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952. https://doi.org/10.1056/NEJMoa032641CrossRefPubMed

20.

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KSC, Schultz CJ, Lee N, Fu KK (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944. https://doi.org/10.1056/NEJMoa032646CrossRefPubMed

21.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. https://doi.org/10.1016/0021-9681(87)90171-8CrossRefPubMed

22.

Pignon JP, le Maitre A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14. https://doi.org/10.1016/j.radonc.2009.04.014CrossRefPubMed

23.

Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP (2005) Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database. Int J Cancer 114(5):806–816. https://doi.org/10.1002/ijc.20740CrossRefPubMed

24.

Mahmood U, Koshy M, Goloubeva O, Suntharalingam M (2011) Adjuvant radiation therapy for high-grade and/or locally advanced major salivary gland tumors. Arch Otolaryngol Head Neck Surg 137(10):1025–1030. https://doi.org/10.1001/archoto.2011.158CrossRefPubMed

25.

Sadetzki S, Oberman B, Mandelzweig L, Chetrit A, Ben-Tal T, Jarus-Hakak A, Duvdevani S, Cardis E, Wolf M (2008) Smoking and risk of parotid gland tumors: a nationwide case-control study. Cancer 112(9):1974–1982. https://doi.org/10.1002/cncr.23393CrossRefPubMed

26.

Şahin MM, Demircan V, Göcek M, Uzunoğlu E, Akmansu M, Sayar E, Kızıl Y, Aydil U (2020) Submandibular gland cancers: prognostic factors and survival analysis. Eur Arch Otorhinolaryngol. https://doi.org/10.1007/s00405-020-05924-wCrossRefPubMed

27.

National Collaborating Centre for C (2016) National institute for health and care excellence: clinical guidelines. In: cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over. National Institute for Health and Care Excellence (UK) Copyright © National Collaborating Centre for Cancer, London

28.

Bjørndal K, Larsen SR, Therkildsen MH, Kristensen CA, Charabi B, Andersen E, Overgaard J, Schytte S, Pedersen HB, Andersen LJ, Johansen J, Godballe C (2016) Does age affect prognosis in salivary gland carcinoma patients? A national Danish study. Acta Oncol 55(sup1):19–22. https://doi.org/10.3109/0284186X.2015.1114671CrossRefPubMed

29.

Sprave T, Rühle A, Stoian R, Weber A, Zamboglou C, Nieder C, Grosu A-L, Nicolay NH (2020) Radiotherapy for nonagenarians: the value of biological versus chronological age. Radiat Oncol 15(1):113. https://doi.org/10.1186/s13014-020-01563-xCrossRefPubMedPubMedCentral

30.

Terhaard CHJ, van der Schroeff MP, van Schie K, Eerenstein SEJ, Lubsen H, Kaanders JHAM, Smeele LE, Burlage FR, van Den Ende PL, Baatenburg de Jong RJ (2008) The prognostic role of comorbidity in salivary gland carcinoma. Cancer 113(7):1572–1579. https://doi.org/10.1002/cncr.23771CrossRefPubMed

31.

Chow R, Bruera E, Temel JS, Krishnan M, Im J, Lock M (2020) Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysis. Support Care Cancer. https://doi.org/10.1007/s00520-019-05261-7CrossRefPubMed

32.

Gilbert J, Li Y, Pinto HA, Jennings T, Kies MS, Silverman P, Forastiere AA (2006) Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 28(3):197–204. https://doi.org/10.1002/hed.20327CrossRefPubMed

33.

Hong MH, Kim CG, Koh YW, Choi EC, Kim J, Yoon SO, Kim HR, Cho BC (2018) Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Head Neck 40(1):55–62. https://doi.org/10.1002/hed.24933CrossRefPubMed

34.

Airoldi M, Pedani F, Succo G, Gabriele AM, Ragona R, Marchionatti S, Bumma C (2001) Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91(3):541–547. https://doi.org/10.1002/1097-0142(20010201)91:3<541:aid-cncr1032>3.0.co;2-yCrossRefPubMed

35.

Alfieri S, Granata R, Bergamini C, Resteghini C, Bossi P, Licitra LF, Locati LD (2017) Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm? Oral Oncol 66:58–63. https://doi.org/10.1016/j.oraloncology.2016.12.016CrossRefPubMed

36.

Akbaba S, Heusel A, Mock A, Held T, Lang K, Hoerner-Rieber J, Forster T, Katayama S, Kargus S, Rieken S, Plinkert P, Herfarth K, Debus J, Adeberg S (2019) The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: a 15-year single-center experience. Oral Oncol 97:115–123. https://doi.org/10.1016/j.oraloncology.2019.08.018CrossRefPubMed

37.

O'Brien CJ, Soong SJ, Herrera GA, Urist MM, Maddox WA (1986) Malignant salivary tumors–analysis of prognostic factors and survival. Head Neck Surg 9(2):82–92. https://doi.org/10.1002/hed.2890090204CrossRefPubMed

38.

Muller von der Grun J, Martin D, Stover T, Ghanaati S, Rodel C, Balermpas P (2018) Chemoradiotherapy as definitive treatment for elderly patients with head and neck cancer. Biomed Res Int 2018:3508795. https://doi.org/10.1155/2018/3508795CrossRefPubMedPubMedCentral

39.

Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582–3589. https://doi.org/10.1200/jco.2007.14.8841CrossRefPubMedPubMedCentral

40.

Schofield CP, Sykes AJ, Slevin NJ, Rashid NZ (2003) Radiotherapy for head and neck cancer in elderly patients. Radiother Oncol 69(1):37–42. https://doi.org/10.1016/s0167-8140(03)00249-4CrossRefPubMed

41.

Douglas JG, Laramore GE, Austin-Seymour M, Koh WJ, Lindsley KL, Cho P, Griffin TW (1996) Neutron radiotherapy for adenoid cystic carcinoma of minor salivary glands. Int J Radiat Oncol Biol Phys 36(1):87–93. https://doi.org/10.1016/s0360-3016(96)00213-1CrossRefPubMed

42.

Jensen AD, Poulakis M, Nikoghosyan AV, Welzel T, Uhl M, Federspil PA, Freier K, Krauss J, Höss A, Haberer T, Jäkel O, Münter MW, Schulz-Ertner D, Huber PE, Debus J (2016) High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years' experience with raster-scanned carbon ion therapy. Radiother Oncol 118(2):272–280. https://doi.org/10.1016/j.radonc.2015.05.010CrossRefPubMed

43.

Sulaiman NS, Demizu Y, Koto M, Saitoh JI, Suefuji H, Tsuji H, Ohno T, Shioyama Y, Okimoto T, Daimon T, Nemoto K, Nakano T, Kamada T (2018) Multicenter study of carbon-ion radiation therapy for adenoid cystic carcinoma of the head and neck: subanalysis of the japan carbon-ion radiation oncology study group (J-CROS) study (1402 HN). Int J Radiat Oncol Biol Phys 100(3):639–646. https://doi.org/10.1016/j.ijrobp.2017.11.010CrossRefPubMed

44.

Griffin TW, Pajak TF, Laramore GE, Duncan W, Richter MP, Hendrickson FR, Maor MH (1988) Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study. Int J Radiat Oncol Biol Phys 15(5):1085–1090. https://doi.org/10.1016/0360-3016(88)90188-5CrossRefPubMed

45.

Paleri V, Wight RG (2002) Applicability of the adult comorbidity evaluation—27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of UK patients with head and neck cancer: a retrospective study. J Laryngol Otol 116(3):200–205. https://doi.org/10.1258/0022215021910528CrossRefPubMed

Title: Radiation-induced toxicities and outcomes after radiotherapy are independent of patient age in elderly salivary gland cancer patients: results from a matched-pair analysis of a rare disease
Authors: Alexander Rühle
Sofie Rothhaar
Erik Haehl
Tobias Kalckreuth
Tanja Sprave
Raluca Stoian
Constantinos Zamboglou
Eleni Gkika
Andreas Knopf
Anca-Ligia Grosu
Nils H. Nicolay
Publication date: 01-07-2021
Publisher: Springer Berlin Heidelberg
Keywords: Radiotherapy
Cytostatic Therapy
Salivary Gland Cancer
Salivary Gland Cancer
Published in: European Archives of Oto-Rhino-Laryngology / Issue 7/2021
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-020-06393-x

2024 ASCO Annual Meeting

Springer Medicine

Radiation-induced toxicities and outcomes after radiotherapy are independent of patient age in elderly salivary gland cancer patients: results from a matched-pair analysis of a rare disease

Abstract

Purpose

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2021

Enlarged vestibular aqueduct and Mondini Malformation: audiological, clinical, radiologic and genetic features

Modified submental platysmal adipomyofascial flap: is it a reliable alternate reconstructive option for small- to mid-sized defects especially in male patients with oral/oropharyngeal cancer?

3D endoscopy shows enhanced anatomical details and depth perception vs 2D: a multicentre study

Relation between auditory memory and global memory in young and older adults

A retrospective study of 30 basal cell adenomas of the salivary gland in a Brazilian population and literature review

The endolymphatic sac tumor: challenges in the eradication of a localized disease